eFFECTOR Therapeutics is a clinical-stage biopharmaceutical company developing cancer drugs that target protein translation — specifically the eIF4F complex — to simultaneously suppress multiple proteins that drive tumor growth, immune evasion, and drug resistance. eFFECTOR calls this drug class selective translation regulator inhibitors (STRIs). The company has two main drug candidates. Tomivosertib is an oral MNK inhibitor designed to reprogram T cells to better attack tumors by reducing immune exhaustion signals; it is being developed in combination with pembrolizumab in frontline non-small cell lung cancer patients with high PD-L1 expression, with a Phase 2b trial (KICKSTART) having completed enrollment. Zotatifin is an IV-administered eIF4A inhibitor targeting a broader set of oncoproteins; it is being evaluated in combination with fulvestrant and abemaciclib in ER+ metastatic breast cancer. eFFECTOR also has an early-stage eIF4E inhibitor program licensed to Pfizer, from which eFFECTOR has received $42M to date, with up to $465M in potential milestones plus royalties. eFFECTOR has no approved products and no product revenue. If tomivosertib or zotatifin are eventually approved, eFFECTOR intends to commercialize them directly in North America through a targeted oncology sales force, and to partner outside North America. With only 14 employees and reliance on external manufacturing, the company's prospects are closely tied to upcoming clinical trial results.